Zingo Demonstrates Efficacy for Pain Reduction in Pediatrics, Study Reveals

Marathon Pharmaceuticals announced positive results from the Phase 3 study of Zingo (lidocaine hydrochloride monohydrate) for the reduction of venous access pain in pediatric patients.

Marathon Pharmaceuticals announced the recent publication of a clinical study confirming that Zingo (lidocaine hydrochloride monohydrate) powder intradermal injection system significantly reduces venous access pain in pediatric patients. The results were published in the journal Clinical Therapeutics.

The Phase 3, randomized, double-blind, placebo-controlled study collected data from 535 patients ages 3–18, who were undergoing venipuncture or peripheral venous cannulation procedures as part of their standard clinical care.

TRENDING ON CPA: The Refill: How Anesthesiologists, Pain Medicine Specialists Can Demonstrate Value — Part 1

The active system group had significantly (P=0.0022) less pain compared with the placebo in all age groups combined. Venous access procedures were performed successfully on the first attempt in 95.5% of the patients in the active treatment group and 96.2% in the placebo group, suggesting that Zingo did not negatively impact the ability to access the vein. Analgesic efficacy was assessed by patient self-report of venous access pain (Wong-Baker FACES Pain Rating Scale [3–18 years] and visual analog scale [VAS; 8–18 years]) and parental observational VAS.

Zingo is a fast acting, easy to use, sterile, needle-free product that, with the push of a button, delivers a 0.5mg dose of powdered lidocaine particles into the skin numbing the site in just one to three minutes. Zingo is currently in use at several major children’s hospitals nationwide.


1. Schmitz ML, et al. Clin Ther. 2015; doi: 10.1016/j.clinthera.2015.05.515.

This article originally appeared on MPR